Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies

References

• Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood J Am Soc Hematol. 2017;130(17):1903–1910.
   Google Scholar
• Kumar A, Soumerai JD, Abramson JS, et al. Preliminary safety and efficacy from a multicenter, investigator-initiated phase ii study in untreated tp53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen). Blood. 2021;138(Supplement 1):3540–3540.
   Google Scholar
• Papin A, Gouill SL, Chiron D. Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment. Leuk Lymphoma. 2018;59(5):1064–1072.
   PubMed Web of Science ®Google Scholar
• MCL Cells in Tumor Microenvironment Impair T-Cell Metabolic Fitness and Effector Function. ASH; 2020.
   Google Scholar
• Balsas P, Veloza L, Clot G, et al. SOX11, CD70 and Treg cells configure the tumor immune microenvironment of aggressive mantle cell lymphoma. Blood. 2021;138(22):2202–2215.
   PubMedGoogle Scholar
• Yang ZZ, Novak AJ, Ziesmer SC, et al. CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4 + CD25− T cells. Blood Am Soc Hematol. 2007;110(7):2537–2544.
   Google Scholar
• Le K, Sun J, Khawaja H, et al. Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis. Blood Adv. 2021;5(14):2863–2863.
   PubMedGoogle Scholar
• Medina DJ, Goodell L, Glod J, et al. Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways. Haematologica. 2012;97(8):1255–1255.
   PubMed Web of Science ®Google Scholar
• Kurtova AV, Tamayo AT, Ford RJ, et al. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood. 2009;113(19):4604–4604.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang J, Qian J, et al. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood. 2012;120(18):3783–3783.
   PubMed Web of Science ®Google Scholar
• Chiron D, Bellanger C, Papin A, et al. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood. 2016;128(24):2808–2818.
   PubMed Web of Science ®Google Scholar
• Zhang S, Jiang VC, Han G, et al. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nat Commun. 2021;12(1):1–17.
   PubMedGoogle Scholar
• Wang L, Qian J, Lu Y, et al. Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica. 2013;98(9):1458–1466.
   PubMed Web of Science ®Google Scholar
• Harrington BK, Wheeler E, Hornbuckle K, et al. Modulation of immune checkpoint molecule expression in mantle cell lymphoma. Leuk Lymphoma. 2019;60(10):2498–2507.
   PubMed Web of Science ®Google Scholar
• Xerri L, Chetaille B, Seriari N, et al. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol. 2008;39(7):1050–1058.
   PubMed Web of Science ®Google Scholar
• Menter T, Bodmer-Haecki A, Dirnhofer S, et al. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. Hum Pathol. 2016;54:17–24.
   PubMed Web of Science ®Google Scholar
• Ek S, Björck E, Högerkorp CM, et al. Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival. Int J Cancer. 2006;118(8):2092–2097.
   PubMedGoogle Scholar
• Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142(5):699–713.
   PubMed Web of Science ®Google Scholar
• Chao MP, Tang C, Pachynski RK, et al. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood Am Soc Hematol. 2011;118(18):4890–4901.
   Google Scholar
• Jm R, A N, P H, et al. Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors. Br J Haematol. 2021;193(3):520–531.
   PubMedGoogle Scholar
• Aprile von Hohenstaufen K, Conconi A, de Campos CP, et al. Prognostic impact of monocyte count at presentation in mantle cell lymphoma. Br J Haematol. 2013;162(4):465–473.
   PubMedGoogle Scholar
• Koh YW, Shin SJ, Park C, et al. Absolute monocyte count predicts overall survival in mantle cell lymphomas: correlation with tumour-associated macrophages. Hematol Oncol. 2014;32(4):178–186.
   PubMedGoogle Scholar
• Nygren L, Wasik AM, Baumgartner-Wennerholm S, et al. T-Cell levels are prognostic in mantle cell lymphoma. Clin Cancer Res. 2014;20(23):6096–6104.
   PubMedGoogle Scholar
• Immune-Depleted Tumor Microenvironment Signature Is Associated with BTK Inhibitor Resistance in Mantle Cell Lymphoma. American Society of Hematology; 2021.
   Google Scholar
• Bernard S, Danglade D, Gardano L, et al. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma. Int J Cancer. 2015;136(12):2761–2774.
   PubMed Web of Science ®Google Scholar
• Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton’s Tyrosine Kinase Inhibitor (BTKi) Therapy. ASH; 2021.
   Google Scholar
• Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–1342.
   PubMed Web of Science ®Google Scholar
• Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31(23):2912–2919.
   PubMed Web of Science ®Google Scholar
• Hagner PR, Chiu H, Ortiz M, et al. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity. Br J Haematol. 2017;179(3):399–409.
   PubMed Web of Science ®Google Scholar
• Marriott J, Clarke I, Dredge K, et al. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol. 2002;130(1):75–84.
   PubMed Web of Science ®Google Scholar
• CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study. Atlanta, Georgia: ASH; 2021.
   Google Scholar
• Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010;150(2):200–208.
   PubMed Web of Science ®Google Scholar
• Else M, Marín‐Niebla A, de la Cruz F, et al. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol. 2012;159(3):322–328.
   PubMedGoogle Scholar
• Torka P, Barth M, Ferdman R, et al. Mechanisms of resistance to monoclonal antibodies (mAbs) in lymphoid malignancies. Curr Hematol Malig Rep. 2019;14(5):426–438.
   PubMedGoogle Scholar
• Hiraga J, Tomita A, Sugimoto T, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood J Am Soc Hematol. 2009;113(20):4885–4893.
   Google Scholar
• Kuroda Y, Yashima-Abo A, Koyama D, et al. Bone marrow stromal cell-mediated degradation of CD20 leads to primary rituximab resistance in mantle cell lymphoma. Leukemia. 2021;35(5):1506–1510.
   PubMedGoogle Scholar
• Dahal LN, Huang C-Y, Stopforth RJ, et al. Shaving is an epiphenomenon of type I and II anti-CD20-mediated phagocytosis, whereas antigenic modulation limits Type I monoclonal antibody efficacy. J Immunol. 2018;201(4):1211–1221.
   PubMedGoogle Scholar
• Skopelja-Gardner S, Jones JD, Hamilton BJ, et al. Role for ZAP-70 signaling in the differential effector functions of rituximab and obinutuzumab (GA101) in chronic lymphocytic leukemia B cells. J Immunol. 2017;199(4):1275–1282.
   PubMed Web of Science ®Google Scholar
• Terui Y, Mishima Y, Sugimura N, et al. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma. Clin Cancer Res. 2009;15(7):2523–2530.
   PubMed Web of Science ®Google Scholar
• Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001;98(12):3383–3389.
   PubMed Web of Science ®Google Scholar
• Racila E, Link BK, Weng WK, et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res. 2008;14(20):6697–6703.
   PubMed Web of Science ®Google Scholar
• Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, et al. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak Expression. Clin Cancer Res. 2008;14(5):1550–1560.
   PubMed Web of Science ®Google Scholar
• Gu JJ, Singh A, Xue K, et al. Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development. Oncotarget. 2018;9(3):4020–4033.
   PubMedGoogle Scholar
• Heinrich DA, Weinkauf M, Hutter G, et al. Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma. Br J Haematol. 2015;168(4):606–610.
   PubMedGoogle Scholar
• Wang ML, Lee H, Chuang H, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016;17(1):48–56.
   PubMed Web of Science ®Google Scholar
• Edelmann J, Dokal AD, Vilventhraraja E, et al. Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways. Iscience. 2021;24(2):102089.
   PubMedGoogle Scholar
• Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009;145(3):344–349.
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Shah B, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015;373(19):1835–1844.
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Eskelund CW, Hutchings M, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018;5(3):e109–e116.
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood J Am Soc Hematol. 2001;98(1):210–216.
   Google Scholar
• Reddy N, Hernandez‐Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008;140(1):36–45.
   PubMed Web of Science ®Google Scholar
• Chiu H, Trisal P, Bjorklund C, et al. Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma. Br J Haematol. 2019;185(2):240–253.
   PubMed Web of Science ®Google Scholar
• Lagrue K, Carisey A, Morgan DJ, et al. Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. Blood J Am Soc Hematol. 2015;126(1):50–60.
   Google Scholar
• Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26(11):2326–2335.
   PubMed Web of Science ®Google Scholar
• Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother. 2009;58(7):1033–1045.
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN). Br J Haematol. 2014;164(6):811–821.
   PubMed Web of Science ®Google Scholar
• Ménard C, Rossille D, Dulong J, et al. Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma. Blood Adv. 2021;5(8):2063–2074.
   PubMedGoogle Scholar
• Menter T, Tzankov A, Zucca E, et al. Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy. Br J Haematol. 2020;189(4):707–717.
   PubMedGoogle Scholar
• Zheng W, Carol E, Alli R, et al. PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells. Leukemia. 2018;32(5):1157–1167.
   PubMed Web of Science ®Google Scholar
• Ruella M, Kenderian SS, Shestova O, et al. The addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma. Clin Cancer Res. 2016;22(11):2684–2696.
   PubMed Web of Science ®Google Scholar
• Rule S, Dreyling M, Goy A, et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica. 2019;104(5):e211–e214.
   PubMed Web of Science ®Google Scholar
• Gauthier J, Hirayama AV, Purushe J, et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 2020;135(19):1650–1660.
   PubMed Web of Science ®Google Scholar
• Patel V, Balakrishnan K, Bibikova E, et al. Comparison of acalabrutinib, a selective bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. Clin Cancer Res. 2017;23(14):3734–3743.
   PubMed Web of Science ®Google Scholar
• Thijs WHF, Charnelle CT, Nan H, et al. Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma. Haematologica. 2020;105(2):e76–e79.
   PubMedGoogle Scholar
• Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma. Atlanta, Georgia: ASH; 2021.
   Google Scholar
• Shah NN, Johnson BD, Schneider D, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020;26(10):1569–1575.
   PubMed Web of Science ®Google Scholar
• Wudhikarn K, Brunstein CG, Bachanova V, et al. Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome. Biol Blood Marrow Transplant. 2011;17(10):1497–1504.
   PubMedGoogle Scholar
• Russell N, Byrne J, Faulkner R, et al. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant. 2005;36(5):437–441.
   PubMed Web of Science ®Google Scholar
• Bloor AJ, Thomson K, Chowdhry N, et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(1):50–58.
   PubMed Web of Science ®Google Scholar
• Tam CS, Bassett R, Ledesma C, et al. Mature results of the MD anderson cancer center risk-adapted transplantation strategy in mantle cell lymphoma. Blood J Am Soc Hematol. 2009;113(18):4144–4152.
   Google Scholar
• Urbano-Ispizua A, Pavletic SZ, Flowers ME, et al. The impact of graft-versus-host disease on the relapse rate in patients with lymphoma depends on the histological subtype and the intensity of the conditioning regimen. Biol Blood Marrow Transplant. 2015;21(10):1746–1753.
   PubMed Web of Science ®Google Scholar
• Cook G, Smith GM, Kirkland K, et al. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2010;16(10):1419–1427.
   PubMed Web of Science ®Google Scholar
• Robinson SP, Boumendil A, Finel H, et al. Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT lymphoma working party. Bone Marrow Transplant. 2018;53(5):617–624.
   PubMed Web of Science ®Google Scholar
• Tessoulin B, Ceballos P, Chevallier P, et al. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. Bone Marrow Transplant. 2016;51(9):1184–1190.
   PubMed Web of Science ®Google Scholar
• Lin RJ, Ho C, Hilden PD, et al. Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP 53 alterations. Br J Haematol. 2019;184(6):1006–1010.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-Targeting T-Cell-Engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-Cell lymphoma: a phase I trial. J Clin Oncol. 2021;39(18):1959–JCO2003175.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021;398(10306):1157–1113.
   PubMed Web of Science ®Google Scholar
• Budde LE, Sehn LH, Assouline S, et al. Mosunetuzumab, a Full-Length bispecific CD20/CD3 antibody, displays clinical activity in relapsed/refractory B-Cell Non-Hodgkin lymphoma (NHL): interim safety and efficacy results from a phase 1 study. Blood. 2018;132(Supplement 1):399–399.
   Google Scholar
• Bannerji R, Allan JN, Arnason JE, et al. Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-Cell Non-Hodgkin lymphoma, including patients refractory to CAR T therapy. Blood. 2020;136(Supplement 1):42–43.
   Google Scholar
• van der Horst HJ, de Jonge AV, Hiemstra IH, et al. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer J. 2021;11(2):38.
   PubMed Web of Science ®Google Scholar
• Jurczak W, Zinzani PL, Hess G, et al. A phase IIa, open-label, multicenter study of single-agent tafasitamab (MOR208), an Fc-optimized anti-CD19 antibody, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma: long-term follow-up, final analysis. Washington, DC: American Society of Hematology; 2019.
   Google Scholar
• Lee HJ, Choi MY, Siddiqi T, et al. Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL). J Clin Oncol. 2021;39(15_suppl):7556–7556.
   Google Scholar
• Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698–2704.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2009;15(20):6446–6453.
   PubMed Web of Science ®Google Scholar
• Frank MJ, Khodadoust MS, Czerwinski DK, et al. Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: a phase I/II trial. J Exp Med. 2020;217(9):e20191712.
   PubMed Web of Science ®Google Scholar
• Kim TM, Lakhani N, Gainor J, et al. ALX148, a CD47 blocker, in combination with rituximab in patients with Non-Hodgkin lymphoma. Blood. 2020;136(Supplement 1):13–14.
   Google Scholar
• Advani R, Bartlett NL, Smith SM, et al. The first-in-class anti-cd47 antibody hu5f9-G4 + rituximab induces durable responses in relapsed/refractory DLBCL and indolent lymphoma: interim phase 1B/2 results. Hematol Oncol. 2019;37:89–90.
   Google Scholar
• Lokhande L, Emruli VK, Kolstad A, et al. Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk. BMC Cancer. 2020;20(1):1–13.
   Google Scholar
• Guo A, Lu P, Coffey G, et al. Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment. Oncotarget. 2017;8(8):12953–12967.
   PubMed Web of Science ®Google Scholar
• Blunt MD, Koehrer S, Dobson RC, et al. The dual syk/JAK inhibitor cerdulatinib antagonizes B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(9):2313–2324.
   PubMedGoogle Scholar
• Papin A, Tessoulin B, Bellanger C, et al. CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages. Leukemia. 2019;33(10):2442–2453.
   PubMed Web of Science ®Google Scholar
• Zhao X, Lwin T, Silva A, et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017;8(1):14920–14915.
   PubMedGoogle Scholar
• Guan J, Huang D, Yakimchuk K, et al. p110α inhibition overcomes stromal cell-mediated ibrutinib resistance in mantle cell lymphoma. Mol Cancer Ther. 2018;17(5):1090–1100.
   PubMedGoogle Scholar
• Eyre TA, Walter HS, Iyengar S, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104(2):e68–e71.
   PubMed Web of Science ®Google Scholar
• Jayappa KD, Portell CA, Gordon VL, et al. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv. 2017;1(14):933–946.
   PubMed Web of Science ®Google Scholar
• Kaplan LD, Maurer MJ, Stock W, et al. Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/alliance 50403. Am J Hematol. 2020;95(6):583–593.
   PubMed Web of Science ®Google Scholar
• Till BG, Li H, Bernstein SH, et al. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol. 2016;172(2):208–218.
   PubMed Web of Science ®Google Scholar
• Oppermann S, Ylanko J, Shi Y, et al. High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. Blood J Am Soc Hematol. 2016;128(7):934–947.
   Google Scholar
• Haselager M, Thijssen R, West C, et al. Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL. Cell Death Differ. 2021;28(5):1658–1668.
   PubMedGoogle Scholar